CA-CEPTON-TECHNOLOGIES
22.9.2020 14:02:08 CEST | Business Wire | Press release
Cepton Technologies, Inc., a leading provider of state-of-the-art, intelligent, lidar-based solutions, has announced details of its groundbreaking automotive-grade lidar sensor – the Vista® -X90, priced at less than $1000 for high volume automotive applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200922005088/en/
The Vista-X90 is the newest addition to Cepton’s Vista-X automotive grade sensor family. It sets a new benchmark for high performance at low power in a compact form factor, and is ideally suited for advanced driver assistance systems (ADAS) and autonomous vehicles (AVs). Weighing less than 900 g, the Vista-X90 achieves up to 200 m range at 10% reflectivity with an outstanding angular resolution of 0.13° and state-of-the-art power consumption of <12W. The sensor supports frame rates of up to 40 Hz.
Optimized for ease of vehicle integration, the Vista-X90 has a licensable design architecture powered by Cepton’s patented Micro Motion Technology (MMT® ) – a frictionless, mirrorless, rotation-free lidar architecture capable of high resolution and long range 3D imaging, while maximizing the sensor robustness and reliability to meet the stringent requirements of automotive applications.
Powered by Cepton’s next generation ASIC technology, the Vista-X90 is an ISO26262 ASIL-B sensor that supports AUTOSAR and over-the-air (OTA) functionality, with advanced capabilities for factory, extrinsic and dynamic calibration. With a width of 120 mm, depth of 110 mm and a front-facing height of <45 mm, Vista-X90 is compact and embeddable. Its 90° x 25° field of view, combined with its directional, non-rotational design allows seamless vehicle integration - such as in the fascia, behind the windshield or on the roof.
Built with easily available and inexpensive components using a highly manufacturable, modular and scalable architecture, the Vista-X90 is ideally suited for high volume production to bring truly cost-effective lidar solutions to ADAS and AV markets. Cepton has licensed its technology to the world’s largest automotive headlamp Tier 1, Koito, who has non-exclusive rights to manufacture and sell Cepton’s lidar technology for an automotive application, using key modules supplied by Cepton.
“We are excited to disrupt the industry with the Vista-X90, which is the most cost-effective, high-performance lidar in the world for automotive applications,” said Dr. Jun Pei, Cepton’s CEO. “Automotive lidars have historically had either low performance at acceptable cost or claimed high performance while being too expensive for many OEM programs. The Vista-X90 fundamentally changes the game by bridging that divide and delivering the optimal mix of performance, power, reliability and cost. This is an integral part of our plan to make lidar available as an essential safety device in every consumer vehicle in the world.”
The Vista-X90 is targeted for production in 2022 and beyond, and samples can be made available upon request .
To learn more about the Vista-X90 and Cepton’s automotive grade lidar capabilities, join Cepton at the upcoming Automotive Lidar 2020 conference next week, between September 22 – 24, 2020. Please visit our virtual booth page and sign up to hear Cepton’s Senior Director of Business Development, Mitch Hourtienne, discuss the Vista lidars in his talk “Importance of Tier 1 Collaboration for an Automotive ADAS Production Program ” on September 23 at 11:15 am EST.
About Cepton Technologies, Inc.
Cepton provides state-of-the-art, intelligent, lidar-based solutions for a range of markets such as autonomous driving , ADAS , intelligent transportation systems (ITS), smart spaces and industrial robotics. Cepton’s patented MMT®-based lidar technology enables reliable, scalable and cost-effective solutions that deliver long range, high resolution 3D perception for smart applications.
Founded in 2016 and led by industry veterans with over two decades of collective experience across a wide range of advanced lidar and imaging technologies, Cepton is focused on the mass market commercialization of high performance, high quality lidar solutions. Cepton is headquartered in San Jose, California, USA, with a presence in Germany, Canada, UK, Japan and India, to serve a fast-growing global customer base. For more information, visit www.cepton.com and follow us on Twitter and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200922005088/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom